key: cord-0776703-45yui9ub
authors: von Kummer, Rüdiger
title: Scientific publishing during the COVID-19 pandemic
date: 2020-11-20
journal: Neuroradiology
DOI: 10.1007/s00234-020-02608-4
sha: edac7e1ccd36eaa9165723f776cad475afde6fd3
doc_id: 776703
cord_uid: 45yui9ub

nan

While celebrating Neuroradiology's 50th anniversary in early 2020 (https://www.springer.com/journal/234/updates/ 17776350), our Editors did not envisage how the global pandemic spread of acute respiratory syndrome coronavirus 2 with severe Coronavirus Disease-2019 (COVID-19) and its concomitant rise of victims since March would impact scientific publishing. Interestingly, when compared to the average monthly rate of submissions in 2019, we observed an almost 60% increase of monthly submissions starting in March 2020. We accelerated the peer-review process by asking for prompt reviews of COVID-19-related articles, were as flexible as possible regarding timelines, and sought articles providing novel neuroimaging aspects of COVID-19. We were happy to publish "COVID-19: A primer for Neuroradiologists" in April [1] . August followed with a pictoral review of "Bilateral lesions of the basal ganglia and thalami (central grey matter)" that included COVID-19-associated acute necrotizing encephalopathy [2] . Although Neuroradiology publishes only exceptional case reports, we presented in September a patient with "COVID-19-induced anosmia associated with olfactory bulb atrophy," who had a pre-COVID MRI for comparison [3] . This report supports the view that the virus may infect olfactory epithelial support cells. Finally, in October, we published another case report, "Acute disseminated encephalomyelitis in a COVID-19 pediatric patient," which clearly illustrates the spectrum of immune reaction of the central nervous system to the virus [4] .

In addition to these remarkable articles, Neuroradiology published 143 original studies, 18 state-of-the-art reviews, six Editorials, two guideline papers, and 13 Letters to the Editor in 2020. I thank our authors, reviewers, editors, the members of the Editorial Board, and Springer's technical team for contributing to the quality of published articles and maintaining high publication ethics standards. My special thanks go to those members who have served for six or more years on our Editorial Board who will now retire to create space for new members.

There is no doubt that the pandemic will continue in 2021. I am confident, however, that vaccination will soon protect those at high risk while new medications and therapies will help prevent poor outcomes. This optimistic view is justified as long as scientists continue to communicate their findings and insights quickly and without restrictions. Ultimately, it is our job to facilitate wide dissemination of evidence-based scientific truths, and together, we will continue to do so.

Acknowledgements Open Access funding enabled and organized by Projekt DEAL.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

COVID-19: a primer for neuroradiologists

Bilateral lesions of the basal ganglia and thalami (central grey matter)-pictorial review

COVID-19-induced anosmia associated with olfactory bulb atrophy

Acute disseminated encephalomyelitis in a COVID-19 pediatric patient